Immunology | Phase I/ Phase II Developments | UNITED STATES

Kezar Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Kezar Provides Statement Regarding COVID-19 Pandemic

Lead Product(s): KZR-616

Therapeutic Area: Immunology

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 09, 2020

Details:

Kezar anticipate delays in their previously anticipated clinical development and data release milestones for KZR-616. However, Phase 1b portion of their MISSION study will continue to receive data.

Equillium

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versu...

Lead Product(s): Itolizumab

Therapeutic Area: Immunology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 30, 2020

Details:

The research, conducted in mouse models, demonstrates that blockade of the CD6-ALCAM pathway with anti-CD6 antibodies reduces incidence and severity of both GVHD and gastro-intestinal inflammation.

Sorrento Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences

Lead Product(s): Resiniferatoxin

Therapeutic Area: Immunology

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2020

Details:

Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts.

Find

Find Immunology Drugs in Phase I/II Clinical Development in UNITED STATES

United States

A collaboration with SCORR Marketing

Product Type

Companies

Kezar Life Sciences

Kezar Provides Statement Regarding COVID-19 Pandemic

Equillium

Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versu...

Sorrento Therapeutics

Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences